{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-011723","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.051390+00:00","generated_at":"2026-06-25T01:20:17.061176+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Finch Therapeutics stockholders elect three Class I directors and ratify Deloitte as auditor","bullets":["36,785,341 shares (77.35% of outstanding) present at June 10, 2022 annual meeting.","Domenic Ferrante, Nicholas Haft, Samuel A. Hamood elected as Class I directors with >26.8M votes for each.","Ratification of Deloitte & Touche as auditor for FY2022 approved: 36,759,831 for, 20,585 against.","Broker non-votes of 7,987,710 on director election; none on auditor ratification."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-011723","json":"https://secwatch.observer/filing/0000950170-22-011723.json","markdown":"https://secwatch.observer/filing/0000950170-22-011723.md","text":"https://secwatch.observer/filing/0000950170-22-011723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022011723/0000950170-22-011723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022011723/fnch-20220610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:20:17.061176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}